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The major development of the past decade in the first-line treatment of recurrent
and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) was the
introduction of cetuximab in combination with platinum plus 5-fluorouracil chemotherapy
(CT), followed by maintenance cetuximab (the “EXTREME” regimen). This regimen is
supported by a phase 3 randomized trial and subsequent observational studies, and
it confers well-documented survival benefits, with median survival ranging between
approximately 10 and 14 months, overall response rates between 36 and 44%, and
disease control rates of over 80%. Furthermore, as indicated by patient-reported outcome measures, the addition of cetuximab to platinum-based CT leads to a significant
reduction in pain and problems with social eating and speech. Conversely, until very
recently, there has been a lack of evidence-based second-line treatment options, and
the therapies that have been available have shown low response rates and poor survival
outcomes. Presently, a promising new treatment option in R/M SCCHN has emerged:
immune checkpoint inhibitors (ICIs), which have demonstrated favorable results in second-line clinical trials. Nivolumab and pembrolizumab are the first two ICIs that were
approved by the US Food and Drug Administration. We note that the trials that showed
benefit with ICIs included not only patients who previously received ≥1 platinum-based
regimens for R/M SCCHN but also patients who experienced recurrence within 6 months
after combined modality therapy with a platinum agent for locally advanced disease. In
this review, we outline the available clinical and observational evidence for the EXTREME
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regimen and the initial results from clinical trials for ICIs in patients with R/M SCCHN. We
propose that these treatment options can be integrated into a new continuum of care
paradigm, with first-line EXTREME regimen followed by second-line ICIs. A number of
ongoing clinical trials are comparing regimens with ICIs, alone and in combination with
other ICIs or CT, with the EXTREME regimen for first-line treatment of R/M SCCHN. As
we eagerly await the results of these trials, the EXTREME regimen remains the standard
of care for the first-line treatment of R/M SCCHN.
Keywords: cetuximab, squamous cell carcinoma of the head and neck, immune checkpoint inhibitor, EXTREME,
platinum-refractory, recurrent and/or metastatic, programmed cell death protein 1, programmed cell death
ligand 1

INTRODUCTION

As more treatment options become available, it is reasonable
to propose that the outcomes for patients with R/M SCCHN
could be optimized with the appropriate succession of treatment
regimens. Maximizing the number of therapy lines and optimizing the order in which therapies are administered has been one
of the most powerful tools for delivering maximum benefit to
patients (17, 18). Therefore, it is important to integrate as many
lines of potentially efficacious therapy as possible into the treatment paradigm to generate a maximally effective and tolerable
multi-line continuum of care.
Here, we review the clinical data and propose an optimal
sequence of systemic therapies to maximize the continuum of care
in R/M SCCHN based on currently available evidence (Figure 1).
Non-systemic therapies (radiation therapy, surgery) are outside
the scope of this manuscript and will not be discussed in detail.

Head and neck cancer accounts for over 500,000 new cases and
nearly 300,000 deaths annually worldwide as of 2012 (1, 2).
Treatment options for patients with this disease vary according
to the disease setting as well as other clinical characteristics.
Patients with localized squamous cell carcinoma of the head and
neck (SCCHN) (American Joint Committee on Cancer stages
I-IVB) are treated with potentially curative therapy using ≥1
treatment modalities [surgery, radiation therapy, chemotherapy
(CT), and biologic therapy]. However, many patients develop
recurrent disease; the recurrence rate in early-stage SCCHN is
≈10–20% (3), whereas the recurrence rate in locally advanced
(LA) SCCHN is ≈50% with a predominance of locoregional failure (4–6). Patients with recurrent or metastatic (R/M) SCCHN
have a poor prognosis with median overall survival (OS) of
under 1 year (7). This population includes patients whose disease recurred locally or who developed distant metastasis after
initial treatment for localized disease and the rare patients with
distant metastasis at first presentation. A small percentage of
patients with localized recurrence can be treated with curative
intent, but the vast majority receive palliative treatment with
systemic therapy. In the first-line treatment of R/M SCCHN,
combination therapy with cetuximab plus cisplatin/carboplatin
plus 5-fluorouracil (5-FU) followed by maintenance cetuximab
(the “EXTREME” regimen) has shown the best results so far in
terms of overall response rate (ORR), progression-free survival
(PFS), and OS (8, 9). A variation on this regimen allows for the
substitution of 5-FU for a taxane (e.g., docetaxel or paclitaxel)
(10, 11). In clinical practice, other combinations, such as a taxane
or cisplatin plus cetuximab, are also sometimes used as first-line
treatment for R/M SCCHN when patients are not fit enough for
the EXTREME regimen, even though these are not evidencebased approaches.
Patients who progress on—or are ineligible for—the
EXTREME regimen and other cetuximab-based first-line treatments have a dearth of efficacious therapeutic options. ORRs to
commonly used therapies (including methotrexate, docetaxel,
paclitaxel, and cetuximab as monotherapies) drop off to well
under 20% and median survival in phase 3 trials has been reproducibly reported at ≈5–6 months (7, 12–16). This grim outlook
for second-line treatment is being reshaped by the introduction
of immune checkpoint inhibitors (ICIs); results of recent trials
will be reviewed here.

Frontiers in Oncology | www.frontiersin.org

AVAILABLE TARGETED THERAPIES
IN SCCHN
Cetuximab

Cetuximab was the first targeted therapy approved in the first line
for R/M SCCHN, conferring survival benefits in combination
with platinum-based CT (7, 9, 19–21). SCCHN tumors are heavily influenced by dysregulation of the epidermal growth factor
receptor (EGFR) pathway, and high EGFR expression is related
to worse outcomes (22). Cetuximab is an immunoglobulin G subclass 1 (IgG1) monoclonal antibody (mAb) targeting the EGFR
by preventing its ligand-mediated activation and dimerization,
and it thus inhibits tumor cell proliferation and stimulates proapoptotic pathways within the tumor cell (23–25). Furthermore,
cetuximab limits EGFR’s potential for translocation into the cell
nucleus and leads to inhibition of double-stranded DNA break
repair by preventing activation of the DNA-dependent protein
kinase. This activity may also have an effect on pathways of tumor
metastasis (26, 27). Finally, the IgG1 isotype allows cetuximab to
induce antibody-dependent cell-mediated cytotoxicity (ADCC),
which is the process of immune cells targeting and killing cells
coated in IgG1 or other isotypes of antibodies (23, 28, 29). In
addition to its apoptosis-inducing, EGFR-blocking activity,
cetuximab directs the ADCC mechanism at tumor cells, using
primarily natural killer (NK) cells to maximize antitumor effects
and thereby representing the first immunotherapy in SCCHN
(Figure 2) (20, 24, 30, 31).
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Figure 1 | New continuum of care for R/M SCCHN. New drugs are under investigation in SCCHN and will change the treatment landscape for R/M disease.
There are now multiple lines of treatment that constitute a continuum of care. The objective of this paper is to define the position of these new drugs in the current
treatment landscape. The algorithm for unfit patients’ needs to be further established in prospective trials. CT, chemotherapy; EXTREME, cetuximab plus cisplatin/
carboplatin plus 5-fluorouracil followed by maintenance cetuximab; PCE, paclitaxel, carboplatin, and cetuximab, followed by cetuximab maintenance until
progressive disease or toxicity; R/M, recurrent and/or metastatic; SCCHN, squamous cell carcinoma of the head and neck; TPEx, cisplatin, docetaxel, cetuximab.
*Other first-line options include cetuximab + cisplatin, cetuximab + paclitaxel and other platinum-based treatments. †Supported by phase 3 trial evidence.

In SCCHN, a highly immunogenic disease, combinations of
immunotherapies such as ICIs, antitumor vaccines, cetuximab
(through ADCC action), and engineered T cells may have the
potential to further improve standard response rates (31). It is
also reasonable to propose that “priming” antitumor immune
responses with cetuximab prior to the administration of other
immunotherapies might augment a patient’s responsiveness
to treatment (31, 36). Contribution of ADCC to the antitumor
activity of cetuximab have not been widely tested in clinical trials,
but recent studies has suggested a correlation between cetuximab
efficacy and high ADCC (37, 38).

Multiple preclinical studies have demonstrated cetuximab’s
ability to stimulate ADCC and affect antitumor immunity. In vitro
evidence shows that cetuximab can mobilize NK cells, activate
neutrophils, and stimulate dendritic cell maturation (20, 23,
29, 30). Furthermore, cetuximab treatment results in an
increase in cytotoxic CD8+ T cells in peripheral blood samples
from patients with SCCHN receiving weekly cetuximab plus
chemoradiotherapy during clinical trials (23). Finally, enhanced
cytotoxic activity has been documented by ex vivo ADCC assays
in patients with R/M SCCHN receiving cetuximab-based therapy,
and induced ADCC was shown to be associated with positive
clinical outcomes (20). Although it is challenging to prove in
clinical studies, data suggest that this property may be involved
in cetuximab’s antitumor activity in humans (23, 24, 29, 30, 32). It
has also been proposed that stimulation of ADCC is an underlying mechanism for cetuximab’s clinically meaningful activity
and the comparatively notable response rates with first- and
second-line treatment in patients with R/M SCCHN, which set it
apart from other mAb EGFR inhibitors (e.g., panitumumab) (33).
Cetuximab can be distinguished from panitumumab in terms of
their differential effect on the immune system. Panitumumab, an
IgG2 antibody with weak ADCC action, had lower clinical activity
as monotherapy (34) and in combination regimens (SPECTRUM,
and other) (35) in R/M SCCHN. Therefore, the advantage in
meaningful clinical activity of cetuximab over panitumumab in
SCCHN may be partially attributed to their effects beyond EGFR
inhibition (notably, panitumumab is a very potent EGFR inhibitor), i.e., to the differential induction of immune response, which
seems to be highly relevant in SCCHN (Figure 2) but less relevant
in colorectal cancer.

Frontiers in Oncology | www.frontiersin.org

Immune Checkpoint Inhibitors

ICIs are a new class of therapeutics in cancer. They function
via the interruption of immunosuppressive pathways, called
inhibitory checkpoints, which are normally used by tumor cells
to prevent detection and elimination by the host immune system (31, 39). Molecular targets of ICIs found on T cells include
cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed
cell death protein 1 (PD-1) receptor. A third common target
is PD-1’s corresponding ligand, PD-L1, found on both tumor
and immune cells (31, 39). ICIs are projected to be particularly
successful in tumors with high levels of endogenous PD-L1
expression, including SCCHN (31). A full list of ICIs currently
in advanced clinical trials for SCCHN can be found in Table 1,
including anti-PD-1 antibodies nivolumab and pembrolizumab,
as well as the anti-PD-L1 antibodies durvalumab and avelumab.
Newer agents targeting immuno-inhibitory (VISTA, Tim-3,
LAG3) or stimulatory (CD137, GITR, OX-40) molecules are
also being studied (40). As of this writing, the bulk of available

3

May 2017 | Volume 7 | Article 72

Argiris et al.

Treatment Options in R/M SCCHN

Figure 2 | Mechanism for cetuximab-mediated antibody-dependent cell-mediated cytotoxicity stimulation. CD, clusters of differentiation; EGFR,
epidermal growth factor receptor; IFN-γ, interferon-γ; NK, natural killer; PD-L1, programmed cell death ligand 1.

Table 1 | PD-1 axis immune checkpoint inhibitors under development for recurrent or metastatic squamous cell carcinoma of the head and neck.
Name

Sponsor

Isotype

Target

Phase

Atezolizumab

Genentech

IgG1

PD-L1

Avelumab

Merck KGaA
Pfizer

IgG1

PD-L1

Durvalumab

MedImmune

IgG1

PD-L1

1
1/2
1
1
1
3
3
1

Ipilimumab

Bristol-Myers Squibb

IgG1

CTLA-4

Nivolumab

Ono/Bristol-Myers Squibb

IgG4

PD-1

Pembrolizumab

MSD

IgG4

PD-1

Tremelimumab

AstraZeneca

IgG2

CTLA-4

3
1
3
3
3
3
1
2
2
3
1

Schedule used in clinical study

Regimen

0.01–20 mg/kg q3w
1,200 mg
1–20 mg/kg q2w (41)
N/A
N/A
1,500 mg q4w (42)
1,500 mg q4w (42)
N/A

Monotherapy
Combination with anti-CD27
Monotherapy
Combination with anti-OX40
Combination with anti-4-1BB
Monotherapy
Combination with anti-CTLA-4
Combination with anti-CTLA-4 and
chemotherapy (CT)
Combination with anti-PD-1
Combination with anti-B7-H3
Monotherapy
Combination with anti-CTLA-4
Monotherapy
Combination with CT
Combination with anti-B7-H3
Combination with anti-EGFR
Monotherapy
Combination with anti-PD-L1
Combination with anti-PD-L1 and CT

N/A
3 mg/kg q3w (43)
3 mg/kg q2w (44)
N/A
200 mg q3w (45)
200 mg q3w (46)
2 mg/kg q3w (47)
2 mg/kg q3w
N/A
75 mg q4w (42)
N/A

CD, clusters of differentiation; CTLA-4, cytotoxic T-lymphocyte antigen-4; EGFR, epidermal growth factor receptor; IgG, immunoglobulin G; N/A, not available; PD-1, programmed
cell death protein 1; PD-L1, programmed cell death ligand 1; q2w, every 2 weeks; q3w, every 3 weeks; q4w, every 4 weeks.
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data on the efficacy of ICIs in SCCHN are derived from trials
with platinum-refractory and second- or later-line R/M SCCHN
patient populations predominantly with an Eastern Cooperative
Oncology Group performance status (ECOG PS) of 0 or 1.

with R/M SCCHN. The primary endpoint of the EXTREME study
was OS, which it met as median OS was significantly improved
from 7.4 to 10.1 months [hazard ratio (HR) = 0.80 (95% CI,
0.64–0.99)] in the CT and cetuximab plus CT arms, respectively
(9). Median PFS was also significantly improved by the addition
of cetuximab to first-line CT, from 3.3 to 5.6 months [HR = 0.54
(95% CI, 0.43–0.67)] (9). The ORR in patients with R/M SCCHN
was nearly doubled upon the addition of cetuximab to CT [36
vs 20%; odds ratio = 2.33 (95% CI, 1.50–3.60)] (9). Finally, the
addition of cetuximab to platinum-based CT led to a significant
reduction in pain and in problems with social eating and speech,
thereby positively impacting social functioning and quality of life
for patients receiving this treatment (49). The toxicity profile of
the EXTREME regimen has been shown to be predictable and
manageable (9).
It is important to note that patients eligible for the EXTREME
regimen in first-line R/M SCCHN are not necessarily treatmentnaïve and may have received previous platinum-containing
therapy (but ≥6 months previously) in the LA SCCHN setting
(9, 52–54). The role of cetuximab in first-line R/M SCCHN specifically for patients who have previously received cetuximab for
LA SCCHN has not been fully investigated, although responsiveness to retreatment in such patients has been documented (55).
In addition, the importance of polychemotherapy in combination
with cetuximab is suggested when considering data from the
randomized trial by Burtness et al., in which cetuximab plus

FIRST-LINE TREATMENT OPTIONS
IN R/M SCCHN
For decades prior to the introduction of the EXTREME regimen
[platinum, 5-FU, cetuximab, followed by maintenance cetuximab
until progressive disease (PD) or toxicity], no experimental treatments yielded any significant increase in survival in patients with
R/M SCCHN.
EXTREME was a randomized phase 3 trial published in 2008,
and the EXTREME regimen became the first to improve PFS and
OS in patients with R/M SCCHN (Table 2) (9, 48). The study
included fit patients (n = 442) with R/M SCCHN, of whom 88%
had ECOG PS 0–1/Karnofsky score ≥80 and 12% had ECOG PS
2/Karnofsky score <80, who were ineligible for local therapy. The
main exclusion criteria were surgery or irradiation within the previous 4 weeks, or previous systemic therapy unless it was part of
a multimodal treatment for LA disease that had been completed
>6 months before study entry (9). The trial investigated whether
the addition of cetuximab to platinum-based CT with cisplatin or
carboplatin plus 5-FU followed by maintenance cetuximab until
PD or toxicity in the first line would improve survival in patients

Table 2 | Cetuximab-based therapy options for first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck.
Name

Regimen

Median PFS,
months

Median OS,
months

ORR, %

EXTREME (n = 442)

Dosage details

Cetuximab + cisplatin/
carboplatin + 5-FU

5.6

10.1

36

• Cisplatin (100 mg/m2 on day 1) or carboplatin (AUC 5 mg/
mL/min, as a 1-h intravenous infusion on day 1)
and 5-FU (1,000 mg/m2 per day for 4 days) every
3 weeks for a maximum of 6 cycles
• Cetuximab (initial dose of 400 mg/m2 as a 2-h
intravenous infusion, then 250 mg/m2 as a 1-h
intravenous infusion per week) for a maximum of 6 cycles

PCE (n = 45)

Cetuximab + carboplatin
+ paclitaxel

5.2

14.7

40

• Paclitaxel (100 mg/m2 on day 1 and 8) and carboplatin
(AUC 2.5 on day 1 and 8), repeated every
3 weeks for up to 6 cycles
• Cetuximab (initial dose of 400 mg/m2, followed by
250 mg/m2 weekly) until PD or unacceptable toxicities

TPEx (n = 54)

Cetuximab + cisplatin
+ docetaxel

6.2

14

44.4

Burtness et al. (50)
(n = 117)

Cetuximab + cisplatin

4.2

9.2

26

• Cetuximab was given (dose of 200 mL/m2)
intravenously on day 1 over 120 min for 1 cycle only;
subsequent cycles were administered at
125 mL/m2/week intravenously over 60 min
• Cisplatin (100 mg/m2) was given on day
1 every 4 weeks

Hitt et al. (51) (n = 46)

Cetuximab + paclitaxel

4.2

8.1

54

• Paclitaxel (80 mg/m2) and cetuximab
(initial dose 400 mg/m2, subsequent
doses of 250 mg/m2) were given weekly
until PD or unacceptable toxicity

• Docetaxel and cisplatin (75 mg/m2 both) on day 1
• Weekly cetuximab 250 mg/m2 (initial dose
of 400 mg/m2)
• Treatment was repeated every 21 days for
4 cycles, followed by maintenance cetuximab
(500 mg/m2) every 2 weeks until PD or unacceptable toxicity

5-FU, 5-fluorouracil; AUC, area under the curve; ORR, overall response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival.
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cisplatin showed improved activity in first-line R/M SCCHN
(ORR was ≥2.5-fold higher in the cetuximab plus cisplatin arm),
but did not show statistically significant OS benefits compared
with cisplatin monotherapy. The results of this trial, however,
are difficult to interpret definitively due to the small sample size
(n = 117 patients) (50).
Over the past decade, retrospective and observational studies have consistently confirmed the benefits of the EXTREME
regimen in patients with first-line R/M SCCHN (9, 11, 56). In the
DIRECT study, prospective data were collected for 154 patients
with untreated SCCHN in the R/M setting receiving cetuximab
according to the EXTREME regimen guidelines (53). The
EXTREME regimen was shown to be feasible in everyday clinical
practice and yielded a median time to progression of 6 months,
which is in line with PFS findings in the EXTREME study (9,
11, 56). Siano et al. have also shown benefits of such regimens in
a retrospective analysis of 117 patients treated with cetuximab
plus platinum-based CT with or without 5-FU in first-line R/M
SCCHN (57). The median OS of 12.4 months was in line with OS
findings for cetuximab plus platinum-based CT in clinical trials
(9, 11, 56). Median PFS and OS during follow-up second-line
treatment with methotrexate, paclitaxel, or other agents were
between 2.6 and 6.1 months, showing the need for stronger
options in later-line treatments of R/M SCCHN. De Mello et al.
also conducted a retrospective study of 121 patients receiving the
EXTREME regimen as first-line treatment in the R/M SCCHN
setting (58). Median PFS and OS were 8 and 11 months, respectively, which are also in line with findings for cetuximab plus
platinum-based CT in clinical trials (9, 11, 56). Similarly, in a
retrospective study of 31 patients with R/M SCCHN, cetuximab
plus CT followed by maintenance with biweekly cetuximab led
to a stable disease rate of 52%, partial response rate of 39%,
and complete response rate of 9% (59). Furthermore, there is
evidence that maintenance therapy until PD with cetuximab as
a single agent following the EXTREME regimen is also welltolerated with a good compliance (relative dose intensity = 82%)
(53, 59). Indeed, in the EXTREME trial, the frequency of severe
skin reactions in the cetuximab-containing arm decreased from
9 to 5% during the cetuximab maintenance phase (median treatment duration = 29.9 weeks) (60).
It is important to point out that in SPECTRUM, an analogous
phase 3 study to the EXTREME trial, the addition of the antiEGFR mAb panitumumab to cisplatin and 5-FU yielded a statistically significant improvement in PFS (5.8 vs 4.6 months) and ORR
(36 vs 25%), but not in OS (35). These data confirm the utility of
anti-EGFR therapy in first-line treatment of R/M SCCHN, while
also suggesting that cetuximab and panitumumab, an IgG1 and
an IgG2 mAb, respectively, do not produce identical survival
outcomes in patients with SCCHN. As previously discussed,
these differential outcomes could be partially attributed to the
distinct property of ADCC stimulation by cetuximab (Figure 2)
that potentially enhances antitumor activity in SCCHN.

5-FU to boost response rates and/or circumvent contraindications to 5-FU (61). Details on regimens and doses are outlined in
Table 2. The TPE (cisplatin, docetaxel, cetuximab) combination
regimen was originally introduced by Argiris et al. in a phase 2
trial in LA SCCHN (62) and was subsequently investigated in the
phase 2 GORTE C 2008-03 study (the so-called “TPEx” regimen)
in the first-line treatment of R/M SCCHN (56). After four cycles
of TPEx, patients without PD received maintenance cetuximab
every 2 weeks until PD. The GORTEC 2008-03 study included a
similar patient population to the EXTREME study, i.e., patients
with previously untreated R/M SCCHN, except for any treatment
received in the LA setting ≥6 months prior to study entry. ORR
in patients who received TPEx was 44.4%, and median OS was
14 months. The PCE regimen similarly consists of paclitaxel,
carboplatin, and cetuximab followed by cetuximab maintenance
until PD or toxicity (Table 2) (11). A trial of PCE, which was
presented at the 2016 annual meeting of the American Society
of Clinical Oncology (ASCO), also included patients who
were EXTREME eligible and received PCE as first-line treatment for R/M SCCHN. ORR was 40% and the median OS was
14.7 months. Finally, a phase 2 study found that cetuximab plus
weekly paclitaxel given in the first line yielded an ORR of 54%
and 10 complete responses (22% of the patient population of
the trial) (51). Overall, cetuximab plus CT-based treatments for
first-line R/M SCCHN are associated with high ORRs, extending
OS and permitting a large number of patients to achieve disease
control. Therefore, in cases of PD on this first-line treatment,
a high number of patients have been able to enter second-line
therapy. Finally, it is important to note that an ongoing phase 2
trial led by GORTEC is comparing TPEx with EXTREME in the
first-line treatment of R/M SCCHN (NCT02268695), with OS
as the primary endpoint and ORR, PFS, and safety as secondary
outcomes. The results of this trial will prove very informative to
oncologists when deciding which regimen is more appropriate
for their patients, except in clear cases where the patient has a
contraindication to 5-FU.

Management of Unfit Patients

Although a patient with an ECOG PS of 0 or 1 would receive
the EXTREME regimen in the first line, a patient with an ECOG
PS of 2 would generally be placed on a single-agent therapy in
the first line, including, but not limited to, targeted therapeutics
such as cetuximab or cytotoxic CT agents such as methotrexate,
docetaxel, paclitaxel, carboplatin, 5-FU, and capecitabine (9, 52,
54, 61). Another option may be the combination of cetuximab
with a taxane for selected patients. However, there are no data
showing benefit from any of these treatments (monotherapy or
combination) in a controlled, randomized trial. For example,
a phase 3 trial that compared gefitinib with methotrexate (the
IMEX trial) and another that compared docetaxel with or without
gefitinib, which both enrolled some patients with an ECOG PS
of 2, failed to show survival benefits with these newer therapies
over standard monotherapy with methotrexate or a taxane
(63, 64). Zalutumumab, an anti-EGFR antibody, did not result in
prolonged OS compared with best supportive care (BSC) alone
(many patients received methotrexate in the control arm) in a
patient population with platinum-refractory R/M SCCHN, which

Using a Taxane Instead of 5-FU
in the Backbone Regimen

Chemotherapy backbones for the EXTREME regimen can be
altered according to patient needs by substituting a taxane for

Frontiers in Oncology | www.frontiersin.org

6

May 2017 | Volume 7 | Article 72

Argiris et al.

Treatment Options in R/M SCCHN

included patients with an ECOG PS of 2 (16). First-line cetuximab vs methotrexate monotherapy is currently being evaluated
in the unfit elderly (≥70 years of age) with R/M SCCHN in a
randomized phase 3 trial (ELAN-UNFIT, NCT01884623).
The use of ICI monotherapy for the treatment of unfit patients
is of interest and deserves clinical study. Given their preferable
toxicity profile and documented activity in SCCHN, we propose
that ICIs can be potentially incorporated in the therapeutic
algorithm (Figure 1). However, it should be recognized that the
activity of ICIs as monotherapy is low and the majority of patients
progress at first reevaluation; therefore, symptomatic patients
with PS of 2 due to disease may deteriorate rapidly.

For the purposes of this review (and based on patient selection
criteria for these trials), fit patients who progress on EXTREME
first-line therapy in the R/M setting will be considered as entering
second- or later-line therapy for R/M SCCHN (52, 54). Fit patients
who progress within 6 months after the last administered dose
of platinum (cisplatin or carboplatin) in either the LA or R/M
setting are, due to this very short duration since the last platinum
treatment, not optimal candidates for platinum retreatment.
These patients have been referred to as “platinum-refractory”
(i.e., also EXTREME-ineligible). Treatment options are very
similar between patients with platinum-refractory disease and
those in second-line R/M SCCHN and, therefore, these two
patient subgroups will be discussed together here and labeled as
“second-line” (68–70). Moreover, most of the second-line trials
in R/M SCCHN have traditionally allowed any number of prior
therapies for R/M disease and, therefore, in these trials, “secondline” therapy implies “second-line and beyond.” Although not
the principal focus of this review manuscript, we will also briefly
discuss recent observations involving kinase inhibitors such as
afatinib (a pan-human EGFR inhibitor, which blocks tyrosine
kinase function in human EGFR 1, 2, and 4) and buparlisib
[targeting phosphoinositol-3-kinase (PI3K)].

Status of ICI Clinical Trials for
First-Line Treatment

Immune checkpoint inhibitors such as nivolumab, pembrolizumab, and durvalumab are currently being investigated in the
first-line R/M SCCHN setting for fit patients, with the EXTREME
regimen chosen as a comparator arm in several recently opened
phase 3 trials (Table 3). Nivolumab in combination with the antiCTLA-4 antibody ipilimumab is compared with the EXTREME
regimen in the CheckMate 651 trial. In contrast, pembrolizumab
is being investigated as a monotherapy as well as in combination
with CT for first-line R/M SCCHN (KEYNOTE-048). Finally,
durvalumab is under examination as a monotherapy and in
combination with the anti-CTLA-4 antibody tremelimumab (the
KESTREL study). However, no results are yet available from these
trials as of the time of this writing and, therefore, use of ICIs in
first-line R/M setting is not recommended outside of clinical
trials (13, 14, 42, 46, 65, 66). Finally, it is worth noting that a
recent trial showed no improvement in outcomes by adding an
immunotherapeutic agent (motolimod) to the EXTREME regimen as quadruplet therapy in first-line R/M SCCHN (67).

Chemotherapy

Available agents for second-line therapy in R/M SCCHN include
methotrexate, docetaxel, and paclitaxel. ORR to methotrexate monotherapy in the second line is 6%, and median OS is
≈6.0 months (15, 63). Second-line treatment with a taxane, such
as docetaxel or paclitaxel, is frequently used in R/M SCCHN
but has not been demonstrated to be superior to other agents in
this setting (16, 61, 64). Additionally, while the CheckMate 141
trial was not designed to compare the three regimens used in the
comparator arm, docetaxel appeared slightly and numerically
superior to methotrexate (and possibly cetuximab, although only
15 patients received this treatment) in terms of OS, although no
concrete conclusions can be drawn, and phase 2 randomized trials suggest no difference in survival between these monotherapies
(44, 71). Irinotecan has also shown some very limited activity in
this setting (7). Combination therapy does not appear to yield
better results than monotherapy as a second-line treatment for
patients with R/M SCCHN. A phase 2 trial of irinotecan and
docetaxel that enrolled patients with good performance status
in second-line treatment showed poor results with an objective
response rate of 3% and a median survival of 5 months (70).

SECOND-LINE AND PLATINUMREFRACTORY OPTIONS IN R/M SCCHN
Over the past decade, patients with second-line R/M SCCHN
predominantly received either single-agent CT or BSC, or they
entered clinical trials (52, 54). Pembrolizumab and nivolumab
were granted US Food and Drug Administration approval in 2016
(August and November, respectively) for use in patients with R/M
SCCHN who progress on or after platinum-based CT, with no
PD-L1 testing requirement in place.

Table 3 | Ongoing studies with immune checkpoint inhibitors in first-line R/M SCCHN vs standard of care (EXTREME regimen).
NCT #

Immunotherapy agent(s) in study

NCT02741570
(CheckMate 651)
NCT02358031
(KEYNOTE-048)
NCT02551159 (KESTREL)

Nivolumab, ipilimumab

Phase

Population

Nivolumab + ipilimumab vs EXTREME

3

Pembrolizumab

3

Durvalumab, Tremelimumab

3

Arms

Previously untreated R/M
SCCHN, ≥6 months since
last dose of platinum

Pembrolizumab vs Pembrolizumab + CT vs EXTREME
Durvalumab vs Durvalumab + tremelimumab vs
EXTREME

CT, chemotherapy; EXTREME, cetuximab plus cisplatin/carboplatin plus 5-fluorouracil followed by maintenance cetuximab; NCT, ClinicalTrials.gov identifier; R/M SCCHN, recurrent
or metastatic squamous cell carcinoma of the head and neck.
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Patients who received BSC for the sole purpose of symptom
management also attained a median OS of ≈5 months (16).

PI3K Inhibition

Advances are being made in the use of PI3K inhibition in
second- or later-line R/M SCCHN therapy. Because the PI3K/
Akt/mTOR pathway is a signaling cascade downstream of the
EGFR that stimulates cell growth and is often dysregulated in
tumor cells, targeting this pathway is one potential method for
overcoming resistance to anti-EGFR targeted therapy (80). The
BERIL-1 trial of the pan-PI3K inhibitor buparlisib (BKM120)
in second- and third-line settings was presented at ASCO 2016.
Buparlisib plus paclitaxel treatment was compared to a placebo
plus paclitaxel regimen in platinum-pretreated patients with one
or two previous lines of therapy in the R/M SCCHN setting. The
response rate to buparlisib plus paclitaxel was 39% (vs 14% in
the comparator arm), with patients achieving a median OS of
10.0 months on this treatment (vs 6.5 months; no indicator of
statistical significance was presented) (81).

Anti-EGFR Therapy

Retreatment with platinum in the setting of platinum-refractory
disease increased toxicity without improving efficacy outcomes
(5, 72). Cetuximab plus cisplatin or carboplatin in platinumrefractory patients within 50 days of the last platinum dose
of the previous regimen in the R/M setting achieved ORRs of
10% with a median OS of ≈6 months (5). Herbst et al. reported
an ORR to cetuximab plus cisplatin of 6% and a median OS
of 4.3 months in patients with platinum-refractory disease if
PD occurred within 90 days of the last platinum dose prior to
entering the study (73).
Cetuximab monotherapy in second-line and platinumrefractory R/M SCCHN populations has been tested in 3 phase
2 clinical trials by Vermorken et al., Baselga et al., and Herbst
et al., involving patients who had progressed on cisplatin- or
carboplatin-based regimens (5, 12, 72, 73). ORRs of 10–13% were
observed. Disease control rates while on cetuximab monotherapy
can top 50%, with median OS of between 5 and 6 months (7,
12, 61, 72). Currently, cetuximab monotherapy is approved in the
US but has not been compared with BSC as of yet.
Finally, as in the first line, cetuximab plus paclitaxel is also
a palliative option in the second-line setting, offering ORRs of
38–55% and median OS of 7.6–10 months (74–76). Cetuximab
plus docetaxel given to patients with R/M SCCHN after failure of
platinum-based therapy resulted in 11% of patients achieving partial responses and 40% achieving stable disease. Disease control
rates were similar between patients with platinum-sensitive and
platinum-refractory disease, and median OS was 6.7 months (77).
Other anti-EGFR therapies have failed to offer higher efficacy
results. Second-line panitumumab monotherapy yielded an ORR
of 4% and a median OS of 5.1 months in the PRISM study (34).
Non-mAb EGFR tyrosine kinase inhibitors such as gefitinib,
erlotinib, lapatinib, and afatinib have also yielded results that
must be regarded as modest at best. In a randomized phase 3
trial, patients who had progressed on or were not fit for standard
first-line therapy received docetaxel plus a placebo or docetaxel
plus gefitinib. ORRs for the docetaxel plus placebo vs docetaxel
plus gefitinib arms were 6.2 and 12.5%, respectively, with a
non-significant improvement in median OS of 1.3 months (from
6.0 to 7.3 months). Similar results have been obtained from the
LUX-Head and Neck 1 trial with afatinib. LUX1 was a randomized
phase 3 trial comparing afatinib vs methotrexate in fit patients with
R/M SCCHN who had progressed on or after first-line platinumbased therapy. When compared with the efficacy of methotrexate
monotherapy described above, afatinib yielded a median OS of
6.8 months (no improvement), with an ORR of 10% (15, 63, 64).
Therefore, afatinib has no survival advantage over methotrexate
in this setting and cannot be considered as an evidence-based
approach in second-line therapy. Another phase 2 trial showed
comparable efficacy with some toxicity profile differences between
cetuximab and afatinib (78). Whether selected patients may benefit from afatinib (e.g., those with p16-negative disease) has yet to
be demonstrated in prospective clinical trials (79).
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ICI Therapy

Currently, ICIs present an efficacious therapeutic option for
patients with R/M SCCHN who have progressed after platinumbased therapy, which supports the emergence of a continuum of
care for R/M disease (Figure 1).
Pembrolizumab and nivolumab approvals in the US for patients
with R/M SCCHN who progress on or after platinum-containing
treatment were based on results from the KEYNOTE-012 and
CheckMate 141 trials. KEYNOTE-012, a non-randomized phase
1b trial with pembrolizumab monotherapy, enrolled 192 patients.
The first 60 patients (“Cohort B”) were selected for PD-L1–positive
tumors and treated with 10 mg/kg pembrolizumab intravenously
every 2 weeks, and the remaining 132 patients (“Cohort B2”)
were unselected for tumor PD-L1 expression and treated with
pembrolizumab at a fixed dose of 200 mg intravenously every
3 weeks (13, 45, 82). Among Cohort B patients (i.e., patients with
PD-L1-positive tumors), 70% had received ≥2 lines of therapy
(13). For this cohort, median PFS and OS were 2 and 13 months,
respectively. In Cohort B2, i.e., patients unselected for PD-L1
expression status, 18% had not received prior therapy in the R/M
setting, while 57% had received ≥2 lines of therapy (45). These
patients achieved a median PFS of 2 months and median OS of
8 months, with tolerable safety. The observed ORR was 18% in
both cohorts (45, 82).
CheckMate 141 was a phase 3 trial that enrolled 361 patients
with R/M SCCHN, of any tumor PD-L1 expression status, who
had disease progression within 6 months after platinum-based CT
(Table 4) (44). Nivolumab 3 mg/kg every 2 weeks was compared to
the investigator’s choice (IC) of standard therapy (methotrexate,
docetaxel, or cetuximab). Nivolumab monotherapy yielded superior OS over standard therapy with a median OS of 7.5 months
(vs 5.1 months with standard therapy) with an HR for death, 0.70
(p = 0.01). However, the median PFS was similar in the two arms
(2 months with nivolumab and 2.3 months with standard therapy,
HR for disease progression or death, 0.89; p = 0.32) and the ORR
was 13.3% with nivolumab vs 5.8% with standard therapy (44).
Notably, at 6 months, the rate of PFS was 19.7% with nivolumab
vs 9.9% with standard therapy, whereas at 1 year, the rate of OS
was 36% with nivolumab vs 16.6% with standard therapy.
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Safety findings from ICI studies with available data indicated
a favorable and tolerable toxicity profile for pembrolizumab
and nivolumab over standard therapies in second-line and
platinum-refractory R/M SCCHN (Table 5). Treatment-related
events occurred in 58.9% (grade 3–4 in 13.1%) and 62% (grade
3–4 in 9%) of patients in CheckMate 141 and KEYNOTE-012,
respectively (44, 45). Finally, patient-reported outcomes from
CheckMate 141 revealed stabilization or slight improvement
in quality of life measures such as social functioning and pain,
while IC monochemotherapy resulted in a clinically meaningful
worsening across many of the same measures (44).
Although ICIs may not improve median PFS, as compared
to IC therapy (Table 5) (13, 14, 31, 65), the subset of patients
who achieve a response or stable disease on ICI treatment tend

to experience a longer duration of response and OS than is to
be expected with standard CT (14, 82, 83). For patients with
SCCHN, ORRs to ICI monotherapy range from 13 to 18%
(Table 4). Somewhat higher tumor responses and survival are
seen with positive tumor PD-L1 expression status even though
patients with PD-L1-negative tumors may also benefit (84).
Other trials of ICI monotherapy are also tackling secondline R/M SCCHN (patient inclusion criteria in Table 4 and full
data summary in Table 5). Ongoing trials with pembrolizumab
include KEYNOTE-040 and MASTERKEY232 (combination
pembrolizumab and talimogene laherparepvec in second-line
and platinum-refractory R/M SCCHN). Upcoming nivolumab
trials in SCCHN include CheckMate 714 (mixed population of
patients with platinum-refractory and first-line R/M SCCHN).

Table 4 | Studies with immune checkpoint inhibitors in mixed-, second-, and later-line settings and platinum-refractory R/M SCCHN.
NCT #

Drug

Phase

Population

Arms

NCT02105636
(CheckMate 141)

Nivolumab

• Platinum-refractory
• Second-/later-line R/M SCCHN

Nivolumab vs IC (cetuximab or docetaxel or
methotrexate)

NCT01848834
(KEYNOTE-012)

Pembrolizumab

1b

• Previously untreated R/M SCCHN, ≥6 months
since last dose of platinum
• Platinum-refractory
• Second-/later-line R/M SCCHN

Pembrolizumab monotherapy

NCT02255097a
(KEYNOTE-055)

Pembrolizumab

2

• Platinum-refractory
• Second-/later-line R/M SCCHN

Pembrolizumab monotherapy

NCT02252042
(KEYNOTE-040)

Pembrolizumab

3

• Platinum-refractory
• Second-/later-line R/M SCCHN

Pembrolizumab vs IC (cetuximab or docetaxel or
methotrexate)

NCT02823574
(CheckMate 714)b

Nivolumab,
ipilimumab

2

• Previously untreated R/M SCCHN, ≥6 months
since last dose of platinum
• Platinum-refractory

Nivolumab + ipilimumab vs Nivolumab + placebo

NCT02369874 (EAGLE)

Durvalumab
tremelimumab

3

• Platinum-refractory
• Second-/later-line R/M SCCHN

Durvalumab vs Durvalumab + tremelimumab
vs IC (fluoropyrimidine, cetuximab, taxane, or
methotrexate)

NCT02207530 (HAWK)

Durvalumab

2

• Platinum-refractory
• Second-/later-line R/M SCCHN

Durvalumab monotherapy

3 (completed)

IC, investigator’s choice; NCT, ClinicalTrials.gov identifier; R/M SCCHN, recurrent and/or metastatic squamous cell carcinoma of the head and neck.
a
All patients in KEYNOTE-055 were also cetuximab-refractory.
b
CheckMate 714 enrolls a cohort of patients in the first-line setting.

Table 5 | Available data for immune checkpoint inhibitor monotherapy in recurrent or metastatic squamous cell carcinoma of the head
and neck (14, 67, 80).a
NCT #

No. of
Patients

NCT02105636 (CheckMate
141) (67)

361

NCT01848834 (expanded
KEYNOTE-012) (80)

60
132

NCT02255097
(KEYNOTE-055) (14)

171

Eligibility

PD-L1+
Any PD-L1
status

Drug

Available data

Toxicity findings

Median
PFS,
months

Median
OS,
months

ORR, %

Nivolumab

2

7.5

13.3

Pembrolizumab

2
2

13
8

18
18

Pembrolizumab

2.1

8

16

13.1% of patients experienced grade 3–4 TRAEs
2 patients died due to TRAE (1 pneumonitis and 1
hypercalcemia)
17% of patients experienced grade 3–4 TRAEs
No treatment-related deaths were reported
About 9% of patients experienced grade 3–4 TRAEs
No treatment-related deaths were reported
26 patients (15%) experienced grade 3–5 TRAEs
1 patient died of treatment-related pneumonitis

NCT, ClinicalTrials.gov identifier; ORR, overall response rate; OS, overall survival; PD-L1, programmed cell death ligand 1; PFS, progression-free survival; TRAE, treatment-related
adverse event.
a
The values in this table reflect the PFS, OS, and ORR recorded for the populations of each trial regardless of PD-L1 expression status (14, 67, 80).
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Finally, ongoing trials with durvalumab include the phase 2
HAWK study (monotherapy in second-line, PD-L1-positive
R/M SCCHN following a single platinum-based treatment), and
the phase 3 EAGLE study (monotherapy or combination with
tremelimumab in second-line R/M SCCHN following a single
platinum-based treatment) (14, 65, 66, 85, 86).

(0.32, 0.99) for patients with p16-positive tumors vs HR (95%
CI) = 0.73 (0.42, 1.25) for patients with p16-negative tumors]
(65). Subgroup analyses of response rates to pembrolizumab by
HPV status revealed that the ORR in patients with HPV-positive
disease was 22 vs 16% in patients with HPV-negative disease in
the KEYNOTE-055 study, and 32 vs 14%, respectively, in the
KEYNOTE-012 study (14, 45). However, neither the effects of
tumor PD-L1 expression nor HPV status are sufficiently robust in
guiding the use of ICI therapy at this time. The analysis of future
randomized trials will be very important in that regard.
Another potential biomarker of response to ICIs is the
interferon-γ (IFNγ) 6-gene signature [CXCL9 (C-X-C motif
chemokine ligand 9), CXCL10 (C-X-C motif chemokine ligand 10),
IDO1 (indoleamine 2,3-dioxygenase 1), IFNG (IFN-γ), HLA-DRA
(major histocompatibility complex, class II, DR α), and STAT1
(signal transducer and activator of transcription 1)] discussed by
Chow et al. in the context of the KEYNOTE-012 study. In this
analysis, a higher IFN-γ 6-gene score was significantly associated
with response to pembrolizumab monotherapy and correlated
with longer PFS and OS. The 6-gene score was not found to correlate in any way with HPV status (87).
Overall, ways for better patient selection for ICI therapy continue to be the subject of ongoing investigations. Nevertheless,
the survival benefits for the subset of patients with pretreated
R/M SCCHN who achieve disease control on ICI monotherapy
are impressive and a breakthrough in clinical practice.

Patient Selection for ICI Therapy: PD-L1
and p16/Human Papillomavirus (HPV)
Status and Other Biomarkers

Based on the available clinical trial-generated evidence, ICIs
present a promising new opportunity for a small number of
patients with very advanced disease who progress on standard
therapy. ORRs to ICIs remain around the 20% mark in secondline patients with R/M SCCHN unselected for tumor PD-L1
expression status. Although data continue to suggest that PD-L1
expression correlates with better efficacy to ICIs, the correlation
is not definitive and no other reliable biomarker for effectively
selecting optimally responsive patient subgroups has been identified as of yet (31, 83). Until additional reliable biomarkers for the
efficacy of PD-1/PD-L1 blockade are identified, patient selection
for pembrolizumab, durvalumab, and nivolumab therapy remains
unsatisfactory. In the CheckMate 141 trial, positive tumor PD-L1
expression appeared to have conferred a numerically higher
survival benefit in patients receiving nivolumab vs IC therapy
[HR = 0.55 (95% CI, 0.36–0.83) in patients with tumors expressing ≥1% PD-L1 vs HR = 0.89 (95% CI, 0.54–1.45) in patients with
tumors expressing <1% PD-L1] (44, 65). However, it is important
to note that the trial was not powered to detect interactions
between tumor PD-L1 expression status and treatment. Subgroup
analyses of KEYNOTE-012 also indicated higher OS and ORR in
patients with ≥1% PD-L1-expressing tumors who had received
≥1 dose of pembrolizumab (45, 87). When immune cells were
included in the PD-L1 expression analysis, ORR rose to 22% in
patients with PD-L1-expressing tumors but dropped to 4% in
those with <1% PD-L1 expression (45). The predictive value of
tumor PD-L1 expression continues to be investigated. Prospective
trial populations will need to be large enough to detect such an
interaction because the sample sizes in trials completed to this
date have been relatively small. Furthermore, there are currently
multiple methodologies available for assessing PD-L1 positivity
and some controversy exists about which cells should be included
in such an analysis (88). Future trials will hopefully educate on
these topics as well. However, it appears that treating patients
with ICIs irrespective of PD-L1 expression status may subject a
larger number of likely non-responders to non-optimal therapy.
At the same time, introducing a minimum PD-L1 expression
requirement will ostensibly preclude a number of responders
from receiving potentially efficacious ICI therapy, which becomes
especially important in the second-line and platinum-refractory
setting where there are few other efficacious treatments.
Additionally, the prognostic value of HPV status appears to hold
up in patients treated with ICIs. In CheckMate 141, patients with
p16-positive tumors experienced a numerically larger magnitude
of benefit from nivolumab treatment as compared to patients
with p16-negative tumors in terms of OS [HR (95% CI) = 0.56
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A NEW CONTINUUM OF CARE
Current clinical and observational evidence in the field supports
the EXTREME regimen as standard of care for fit patients with
R/M SCCHN in the first line, followed by the new treatment
option of ICIs in second line (Figure 1). Maximizing the number
of therapy lines and optimizing the order in which therapies are
administered has historically been one of the most powerful
tools for delivering maximum benefit to the greatest number of
patients (17, 18). Until recently, this strategy has not been feasible
in the treatment of R/M SCCHN; however, the emergence of ICIs
has provided new options for an optimized continuum of care.
The majority of patients who do not respond during first-line
treatments deteriorate rapidly; therefore, providing a continuum
of care successfully requires maximizing the number of responses
in first-line while patients are still relatively fit, thus allowing
them to continue onto a second or third line of treatment. Indeed,
responses are very important in patients with symptomatic
disease, especially those with locoregional progression that can
have devastating consequences. As the efficacy and safety of the
EXTREME regimen are reproducible in observational studies,
physicians’ decision-making when selecting and sequencing
suitable therapies for patients with R/M SCCHN clearly pays off
in clinical practice (57). Presently, there are no efficacy data for
the reverse sequence (i.e., first-line ICIs followed by second-line
utilization of the EXTREME regimen), or for robust follow-up
therapeutic options for patients who progress on ICI treatment.
Finally, platinum remains an important treatment component in
SCCHN, and failure to treat with platinum-based CT in the first
line could deprive patients of a line of therapy (5, 9, 52, 54, 73).
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Notably, our proposed sequence of treatments circumvents these
potential limitations. In summary, until data for ICI function in
first-line R/M SCCHN are published, the treatment sequence of
first-line EXTREME regimen followed by second-line ICIs is the
only evidence-based approach, and thus off-label use of ICIs in
the first-line treatment of fit patients should be discouraged for
the time being.
There are also additional unknowns, stemming from the relative novelty of ICI therapy, that further complicate the therapy
selection process. For example, although ICIs confer OS benefits
as compared to the rest of the available second-, later-line, and
platinum-refractory setting therapeutics, there is still a clear
need for biomarkers of response in order to improve patient
selection, boost ORRs, and prolong PFS time (13, 14, 65, 82).
Other observations associated with ICI monotherapy, including
accelerated tumor growth rate (hyperprogression) in up to 9% of
patients with various tumor types (89) and low median PFS in
R/M SCCHN (44, 45, 82), also suggest that this treatment option
is not yet ready to be administered in the first-line setting without
supporting data from prospective clinical trials. Indeed, the use of
first-line ICIs outside of a clinical trial (i.e., non-evidence-based
use) may subject patients to the risk of early progression with
worsening symptomatology and performance status, and a lower
likelihood of staying sufficiently fit to receive additional therapy.
Therefore, as the EXTREME and similar regimens result in 80%
disease control rates with a median PFS of ≥5 months, these treatment options should continue to precede ICIs in the continuum
of care for fit patients with R/M SCCHN.

promising OS results as monotherapies with tolerable toxicities
and improvements in patient-reported outcomes in patients with
R/M SCCHN in the second-, later-line, and platinum-refractory
setting. Although the full extent of ICI functionality in different
tumor types and therapy lines is still being discovered, we nevertheless anticipate that the pool of ICI-eligible patients will expand
as data become available. The EXTREME regimen is supported by
over 10 years of evidence, and its role in R/M SCCHN has been
fully defined through years of clinical trials and observational
studies. Given the impressive efficacy of ICIs in pretreated R/M
SCCHN, the new challenge facing physicians is deciphering how
to sequence available therapies optimally to maximally prolong
patient survival, while maintaining the highest possible quality of
life. Presently, the only evidence-based sequence places ICIs in the
second-line and platinum-refractory settings, where they offer a
promising alternative to historic therapeutic options. Therefore,
fit patients with R/M SCCHN should continue to receive the
EXTREME regimen in the first-line setting with cetuximab until
PD. Quite excitingly, for the first time in a decade, physicians are
able to offer patients with R/M SCCHN a continuum of care with
efficacious therapy in multiple lines. Naturally, this treatment
paradigm may evolve as additional data emerge.
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